Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02657551 · ClinicalTrials.gov registry record · Phase 2

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

A Phase 2 study of Thyroid Cancer, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
Phase 2
Development phase
8
Enrollment target
2
Study locations

NCT02657551 is a Phase 2 study of Thyroid Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 8 participants, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02657551, a Phase 2 study of Thyroid Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
8 participants
Enrollment target
2
Study locations

Study Summary

This research study is studying a targeted therapy as a possible treatment for thyroid cancer. A targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. \- The name of the study intervention involved in this study is regorafenib.

Conditions Studied

Thyroid Cancer

Interventions

  • DRUG Regorafenib

Study Locations (2)

Connecticut

  • Yale Cancer Center - New Haven

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2016-01
Est. Completion 2025-12
Phase Phase 2

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02657551

The ClinicalTrials.gov registry entry for NCT02657551 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Regorafenib is the first listed.

NCT02657551 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02657551 about?

NCT02657551 is a clinical study titled "A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer". This research study is studying a targeted therapy as a possible treatment for thyroid cancer. A targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. \- The name of the study intervention in...

What is the current status of trial NCT02657551?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-01. Estimated completion is 2025-12.

What conditions does trial NCT02657551 study?

This clinical trial studies the following conditions: Thyroid Cancer.

What interventions are being tested in trial NCT02657551?

The interventions under investigation include: Regorafenib (DRUG).

Who is sponsoring clinical trial NCT02657551?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02657551 being conducted?

This trial has 2 study locations across Connecticut, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thyroid Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Thyroid Cancer

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.